Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.

@article{Seko2017EffectOS,
  title={Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus.},
  author={Yuya Seko and Yoshio Sumida and Saiyu Tanaka and Kojiroh Mori and Hiroyoshi Taketani and Hiroshi Ishiba and Tasuku Hara and Akira Okajima and Atsushi Umemura and Taichiro Nishikawa and Kanji Yamaguchi and Michihisa Moriguchi and Kazuyuki Kanemasa and Kohichiroh Yasui and Shunsuke Imai and Keiji Shimada and Yoshito Itoh},
  journal={Hepatology research : the official journal of the Japan Society of Hepatology},
  year={2017},
  volume={47 10},
  pages={1072-1078}
}
AIM No pharmacological therapies have been established for non-alcoholic fatty liver disease (NAFLD). Sodium glucose cotransporter 2 inhibitor (SGLT2I) was developed for the treatment of adults with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy of SGLT2I in NAFLD patients with T2DM. METHODS Twenty-four biopsy-proven NAFLD patients with T2DM who received SGLT2I for 24 weeks were retrospectively enrolled as the SGLT2I group. Another 21 NAFLD… CONTINUE READING
7 Citations
17 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Treatmentwith the SGLT 2 inhibitor luseogli fl ozin improves nonalcoholic steatohepatitis in a rodentmodel with diabetesmellitus

  • S Qiang, SenoY Nakatsu Y
  • DiabetolMetab Syndr
  • 2015

Treatmentwith the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodentmodel with diabetesmellitus.DiabetolMetab

  • S Qiang, Y Nakatsu, SenoY
  • Syndr 2015;
  • 2015

Similar Papers

Loading similar papers…